Across TCGA pan-cancer cohorts, MAGEB18 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MAGEB18’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MAGEB18 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAGEB18 is over-expressed in tumor.
BRCA, HNSC, and LUSC are the cancer types where MAGEB18 tumor–normal differential expression is most reproducible.